Represent the number of clinical studies conduct.

No definition available.

Name:	cycc_ConductClinicalStudies
Namespace Prefix:	cycc_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of milestones earned during the period per the terms of the license agreement.

+ References

No definition available.

+ Details

Name:	cycc_LicenseAgreementMilestonesEarned
Namespace Prefix:	cycc_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The required notification period for right of first refusal if entity elects to appoint a third party to develop or commercialize a sapacitabine-based product in Japan.

+ References

No definition available.

+ Details

Name:	cycc_LicenseAgreementNoticePeriodForRightOfRefusalForThirdPartyAppointmentToDevelopOrCommercializeSapacitabineBasedProductInJapan
Namespace Prefix:	cycc_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the notice period for the termination of license after a launch of a sapacitabine-based product, or by either party for material default.

+ References

No definition available.

+ Details

Name:	cycc_LicenseAgreementNoticePeriodForTerminationOfAgreementAfterLaunchOfSapacitabineBasedProductOrInCaseOfMaterialDefault
Namespace Prefix:	cycc_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the period for which royalties will be paid following the first commercial sale of licensed products in the country.

+ References

No definition available.

+ Details

Name:	cycc_LicenseAgreementPeriodForRoyaltiesPaymentAfterFirstCommercialSaleOfLicensedProductsInCountry
Namespace Prefix:	cycc_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The potential future milestone payments required to be made under certain contractual agreements.

+ References

No definition available.

+ Details

Name:	cycc_LicenseAgreementPotentialFutureMilestonePayments
Namespace Prefix:	cycc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the notice period for the termination of license by the reporting entity for technical, scientific, efficacy, safety, or commercial reasons.

+ References

No definition available.

+ Details

Name:	cycc_LicensingAgreementNoticePeriodForTerminationOfAgreementDueToTechnicalScientificEfficacySafetyOrCommercialReason
Namespace Prefix:	cycc_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

It represents term of agreement.

+ References

No definition available.

+ Details

Name:	cycc_TermOfAgreement
Namespace Prefix:	cycc_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_SupplyCommitmentLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=cycc_ClinicalCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cycc_MdAndersonMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=cycc_DaiichiSankyoCompanyLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Significant Contracts (Narrative) (Details) $ in Millions		12 Months Ended
Significant Contracts (Narrative) (Details) $ in Millions	Oct. 01, 2018 item	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Clinical Collaboration Agreement [Member] \| The University of Texas MD Anderson Cancer Center [Member]
Supply Commitment [Line Items]
Term of agreement	3 years
Number of clinical studies conducted \| item	4
Daiichi Sankyo
Supply Commitment [Line Items]
Future milestone payments payable		$ 10.0
Period for which royalties will be paid following first commercial sale of licensed products		10 years
Notice period for termination of license by the entity for technical, scientific, efficacy, safety, or commercial reasons		6 months
Notice period for termination of license after launch of a sapacitabine-based product by the entity, or by either party for material default		12 months
Notice period for right of first refusal if third party to be appointed to develop or commercialize a sapacitabine-based product in Japan		60 days
Milestones earned		$ 0.0	$ 0.0